Build your career on Magnet.me
Create a profile and receive smart job recommendations based on your liked jobs.
As a leading provider of innovative technologies for the treatment of Atrial Fibrillation (Afib) and related conditions, electrophysiologists and cardiothoracic surgeons around the globe count on AtriCure to deliver best-in-class solutions that can treat even the most complex cases. Our Isolator® Synergy™ Ablation System is the first and only medical device approved by the FDA for the treatment of long standing persistent Afib, our AtriClip Left Atrial Appendage (LAA) Exclusion System products are the most widely used LAA management devices worldwide, and we are expanding into pain management therapies. We invest in innovation, clinical science, and education to focus on improving lives for our patients worldwide.
AtriCure is seeking a highly experienced and strategic Director, Associate General Counsel to join our global legal team. This role is pivotal in delivering high-quality legal solutions across departments and international entities, supporting a fast-paced and innovative medical device company.
You’ll lead complex legal matters, manage international contracts, and advise senior leaders on regulatory, employment, and governance issues. This is a unique opportunity to shape legal strategy, drive compliance, and support global growth.
This position is ideally based out of our Amsterdam office!
At AtriCure, we’re committed to innovation, collaboration, and improving lives. You’ll be part of a purpose-driven team making a global impact in cardiac care. We offer a dynamic work environment, opportunities for growth, and the chance to shape the future of our EMEA business.
In Addition, AtriCure Also Provides:
Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 150,000 implanted to date.
View what's on offer:
Change language to: Dutch
This page is optimised for people from the Netherlands. View the version optimised for people from the UK.